{"preliminary_commentary":{"by_channel":{"x_thread":26,"podcast":8,"youtube":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02756793\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"STOP","nct_id":"NCT02756793","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=stop-nct02756793. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patient treatment may include the following 3 options, at the discretion of the treating physicians:\n\n* Continue with current systemic agent(s)\n* Observation\n* Switch to next-line treatment","label":"Standard of Care Treatment","type":"ACTIVE_COMPARATOR"},{"description":"SABR is delivered to all sites of progressive disease with continuation of current systemic agents. Further oligo-progressive lesions may be treated with SABR if possible. Upon progression at sites not amenable to SABR, the patient may receive any of the options in Arm 1.","label":"Stereotactic Ablative Radiotherapy (SABR)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-06","type":"ESTIMATED"},"conditions":["Metastatic Cancer"],"enrollment":{"count":90,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Stereotactic Ablative Radiotherapy (SABR)","otherNames":[],"type":"RADIATION"},{"name":"Standard of Care Treatment","otherNames":[],"type":"OTHER"}],"last_update":"2025-12-31","lead_sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","official_title":"Stereotactic Radiotherapy for Oligo-Progressive Metastatic Cancer (The STOP Trial): A Randomized Phase II Trial","overall_status":"ACTIVE_NOT_RECRUITING","phases":["NA"],"primary_completion_date":{"date":"2022-07-31","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-Free Survival","timeFrame":"5 years"}],"references":[{"citation":"Schellenberg D, Gabos Z, Duimering A, Debenham B, Fairchild A, Huang F, Rowe LS, Severin D, Giuliani ME, Bezjak A, Lok BH, Raman S, Chung P, Zhao Y, Ho CK, Lock M, Louie AV, Lefresne S, Carolan H, Liu M, Yau V, Ye A, Olson RA, Mou B, Mohamed IG, Petrik DW, Dosani M, Pai H, Valev B, Gaede S, Warner A, Palma DA. Stereotactic Ablative Radiation for Oligoprogressive Cancers: Results of the Randomized Phase 2 STOP Trial. Int J Radiat Oncol Biol Phys. 2025 Jan 1;121(1):28-38. doi: 10.1016/j.ijrobp.2024.08.031. Epub 2024 Aug 19.","pmid":"39168356","type":"DERIVED"},{"citation":"Lee J, Koom WS, Byun HK, Yang G, Kim MS, Park EJ, Ahn JB, Beom SH, Kim HS, Shin SJ, Kim K, Chang JS. Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2022 Jun;21(2):e78-e86. doi: 10.1016/j.clcc.2021.10.009. Epub 2021 Nov 18.","pmid":"34903471","type":"DERIVED"}],"start_date":{"date":"2016-10"},"study_type":"INTERVENTIONAL","title":"Stereotactic Radiotherapy for Oligo-Progressive Metastatic Cancer (The STOP Trial)","url":"https://clinicaltrials.gov/study/NCT02756793"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/stop-nct02756793"}